Key facts
- Notable investors include Ningbo Angel Capital Guiding Fund, DFJ Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Tongeye
- ·The full record, as it builds
Funding rounds
No funding rounds for Tongeye are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tongeye
Developer of cell therapy drugs intended for ophthalmic diseases. The company leverages multiple research and development pipelines to transplant unique naive retinal pigment epithelium cells derived from induced pluripotent stem cells for treating dry retinal degeneration with an efficient induction and differentiation method backed by independent intellectual property rights, it has reduced costs, improved accessibility, and accelerated the traditional differentiation cycle, serving clients worldwide to improve vision for patients with dry retinal degeneration.
- Sector
- Healthcare
- HQ
- Ningbo, China
- Founded
- 2023
- Website
- tongeye.com/
- Ownership
- Privately Held (backing)
Tongeye doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tongeye shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tongeye in its N-PORT filings yet. We sweep new filings monthly.